Two ongoing and three completed clinical trials evaluated the safety and efficacy of the humanised IgG1 monoclonal anti-PD-L1 antibody atezolizumab (MPDL-3280A), in combination with the anti-CD20 antibody obinutuzumab, for the treatment of aggressive B-cell lymphoma. This evidence concerns the gene CD274 and B-cell non-Hodgkin lymphoma.